The University of Warwick Library - WebBridge

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer : ARTemis Trial
Earl, H. M..  Annals of Oncology.  v. 28. no. 8.   2017-08-01. p. 1817 - 1824... issn: 0923-7534 .   

Online access not found

Sorry - based on the information provided, WebBridge cannot offer appropriate links.